Please login to the form below

patents

This page shows the latest patents news and features for those working in and with pharma, biotech and healthcare.

Enanta takes legal action against Pfizer over Paxlovid patent infringement

The lawsuit claims the oral COVID-19 antiviral infringes on Enanta’s 11, 358, 953 patent. ... The lawsuit claims Pfizer’s oral COVID-19 antiviral infringes on one of Enanta’s patents – patent 11, 358, 953 – and therefore seeks to claim damages

Latest news

Sandoz launches ‘Act4Biosimilars’ initiative to address global health inequalities

Biosimilars can be used as an alternative to biological drugs once the patents have expired and are used to treat a variety of diseases such as cancer, diabetes, arthritis and psoriasis.
Almirall and Inserm Transfert to develop innovative vitiligo treatments

According to the terms of the agreement, Almirall has received global rights to Inserm’s background patents on the use of Wnt agonists in the treatment of vitiligo.
AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris

The two companies will withdraw patent infringement proceedings filed with the US and Japan. ... The agreement resolves all patent disputes between the two companies regarding Ultomiris (ravulizumab) – Alexion’s long-acting complement C5 inhibitor
Moderna clashes with US government over COVID-19 vaccine

Following those rules, as we must, Moderna is required to only list Moderna scientists as the inventors for the patent claims to mRNA-1273,” said the company. ... Moderna’s conclusion is driven by nothing other than our obligation to comply with US
Democrats in the US agree plan to curb drug prices

Under the proposal, most drugs would retain patent exclusivity for nine years before negotiations could start, 12 years for biologics.

More from news
Approximately 71 fully matching, plus 1,624 partially matching documents found.

Latest Intelligence

Piloting a route to the biosimilars opportunities in Europe

As these therapeutics become trusted and more widely used by clinicians, we can expect a larger number of new biosimilars coming onto the market as the patents and market exclusivity linked ... By 2023, patents will expire for most formulations, creating
Transforming clinical trial data into a long-term asset

These might be licensed drugs that could hold potential for a patent extension, or drugs which failed efficacy trials for an intended indication.
The pandemic preparedness paradox

The result is impressive: two granted patents. every day. There is plenty of invention.
The US celebrates five years of biosimilars on the market – a look to the past, present and future

However, various barriers continue to inhibit biosimilars from realising their full potential, driven by patent disputes and formulary challenges which prevent more robust biosimilar adoption. ... Ongoing patent litigation has slowed biosimilar market
Switzerland: a life sciences hub

Inventions and patents. In 2019, Switzerland also filed a record number of patent applications per capita overall. ... Secondly, the revised Patents Act encourages the development of safe medicinal products for paediatric use.

More from intelligence
Approximately 3 fully matching, plus 134 partially matching documents found.

Latest appointments

Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team

He has had the opportunity to work across the full spectrum of the drug lifecycle, from discovery to patent expiry, and his operational and strategic experiences will be vital assets that
Greg Perry joins IFPMA as assistant director general

Perry, who was most recently executive director of the Medicines Patent Pool in Geneva, will move to the global industry body in February. ... He has more than 20 years’ leadership and advocacy experience in the public healthcare arena, most recently
Novartis Oncology head Bruno Strigini to retire

He has navigated the business unit through the Gleevec patent expiration and has led the successful integration of the GSK Oncology Product Portfolio acquired in 2015.
Rubius Therapeutics strengthens senior team

His experience includes establishing the legal department at Millennium Pharmaceuticals - now Takeda Oncology - and served as its associate general counsel and chief patent counsel for several years.
MRC Technology appoints director of technology transfer

Farquharson is additionally appointed to the EU Commission's Expert Group, advising on the European Biotech Directive's impact on patent law and R&D activities.

More from appointments
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest from PMHub

Learning to invest in doctors’ education

The industry is well-used to taking a long-term approach to drug development cycles, therapy area endeavours and drug patent lifecycles.
Protecting Ownership of Technological & Pharmaceutical Innovation

Joshua Goldberg, Co-Managing Partner at Nath, Goldberg &Meyer, discusses key intellectual property issues and pitfalls in the digital health space, the importance of international patent protection, and why it’s ... important to reduce the patent
Three strategies for managing loss of exclusivity successfully

Patent losses could sink Allergan”. 1. “Drug prices to plummet in wave of expiring patents”. ... 5. Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively.
Covid-19: how is it affecting prescribing patterns?

From March 2019, use of on-patent Etanercept, Adalimumab and Rituximab went down, while the Adalimumab biosimilar went up and so did Etanercept and Rituximab biosimilars. ... Or, for companies with on-patent drugs experiencing a sustained drop in sales,
Fishawack Health, a new breed of global commercialization partner, fit for a post pandemic world

We’re designed to solve these challenges by providing integrated, agile solutions across the entire product life cycle, from clinical development to loss of patent.”.

More from PMHub
Approximately 2 fully matching, plus 42 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

Business Development Manager, Medical Education - exciting new U...: Up to £60K base

Medical Writer, MRNA/ Covid 19, Medical Communications, UK: Highly competitive salary

Vice President, Medical Communications, UK, six figure package: Six figure salary

Programme Manager/ Consultant – respiratory health education and...: Negotiable

Scientific Strategy Lead, Medical Communications, UK: Highly competitive salary

Senior Analyst, Market Access, UK, Home based: Highly competitive salary

PMHub

Add my company

M3 (EU)

M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions: Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep: The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool: Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....

Email:
Password:

Please login to the form below

patents

Subscribe to our email news alerts

Featured jobs

Quick links